REVTORPYK is the first and only FDA-approved therapy that inhibits all class I PI3K isoforms (α, β, δ, γ) and mTOR complexes mTORC1 and mTORC2 In the Phase 3 VIKTORIA-1 trial, REVTORPYK combined with ...

A recent study indicates that breast cancer detected after childbirth could be more aggressive as pregnancy and lactation ...

What comes after trastuzumab deruxtecan?

Unexpectedly catapulted into global fame as a COVID-19 vaccine maker, BioNTech is on the verge of returning to its oncology ...

Gedatolisib is the first approved agent to inhibit class I PI3K isoforms plus both mTOR complexes, addressing a long-standing challenge in comprehensive PI3K/AKT/mTOR pathway blockade. The indication ...

Brain metastases are a major challenge in HER2-positive metastatic breast cancer; epidemiologic series suggest that roughly 30%–50% of patients eventually develop brain involvement, which is ...

HER2-positive breast cancer is driven by HER2 protein overexpression, historically linked to poor outcomes but now improved by targeted therapies. Treatment varies by stage, involving surgery, ...

Pfizer has rolled out detailed trial data suggesting Tukysa could be part of a new first-line treatment to delay the progression of HER2-positive breast cancer. The current standard of care for the ...

Distinguishing cancer cells from healthy cells is a central challenge in cancer treatment. Ideal therapies selectively kill cancer cells while leaving healthy cells healthy and able to perform their ...

What Is Hyrnuo, and Why Does It Matter? Hyrnuo (sevabertinib) is a new oral medicine for adults with advanced nonsquamous non-small-cell lung cancer (NSCLC) carrying a specific genetic change known as ...

This position with Christus St. Vincent is an opportunity to help more women battling breast cancer. Christus is known ...